An early assessment during treatment showed that this triple combination therapy, when compared to the dual combination of anti-PD-1 and anti-CTLA-4, further increased the proportion of tumor-infiltrating CD4+ and CD8+ T cells capable of producing both IFN-γ and TNFα 196. The gene discussed is CTLA4; the disease is neoplasm.